BUTADION

 

StockNo	Product description	Status
EB0280-421-06	BUTADION DRAGEE 200 MG X 20

 

COMPOSITION:
Phenylbutazone 200 mg in one dragee

ACTION:
Nonsteroid antiphlogistic agent. It reduces the temperature (by increasing heat release from the body through peripheral vasodilation and profuse perspiration). Its pain-relieving action is associated with the inhibition of prostaglandin biosynthesis and in that respect it is better than acetylsalicytic acid, but its antiphlogistic action is less manifested. It reduces the content of uric acid in the blood. Enhances the tubular reabsorbation of sodium chloride and reduces diuresis (thus favoring the formation of edemas). It suppresses platelet aggregation to a certain extend and at the same time it can inhibit leuko- and thrombocytopoiesis.

PHARMACOKINETICS:
It is quickly absorbed and retained in the blood for a relatively long period: the therapeutic level is attained within two hours, but its biological half-degradation is up to 72 h and can be detected in the body by day 21 after its intake. It binds reversibly to proteins in the serum: to a high percentage (up to 99 %).

INDICATIONS:
Rheumatic diseases: acute articular rheumatism, acute and subacute rheumatoid arthritis and other polyarthrites, rheumatic pericarditis, pleuritis and polyserositis, iridocyclitis (with rheumatic genesis). Painful arthropathies, arfthrosis, spondylosis (particularly with marked inflammatory character); Bechterew's disease; acute attack of gout, psoriatic arthritis; periarthritis, tendoperiostitis, fibrositis, myositis; sometimes in erythema nodosum, lupus erythematodes disseminatus, chorea minor.
Other diseases: discopathies, myalgia, lumbago, sciatica; neuritis, neuralgia; adnexitis, salpingitis, parametritis; contusion, distortion, traumatic luxation, thrombophlebitis of the lower extremities and of hemorrhoidal veins; herpes zoster; diabetes inspidus.

CONTRAINDICATIONS:
Ulcer disease of stomach and duodenum; decompensated renal and hepatic diseases; diseases of the hematopoietic organs (leukopenia in particular); cardiac decompensation. It should not be prescribed to breast-fed babies and little children.

PRECAUTIONS:
To avoid gastrointestinal complaints, butadion should be taken during meals or after meals, in combination with non-alkalizing antacids (e.g. alumoxide). Table salt should be restricted so as to reduce the retention of water and the appearance of edemas; white blood count should be checked regularly during treatment, particularly in diseases which can progress with damage to the bone marrow (septic states, rheumatic diseases with anemia, tonsillitis), and after long-term treatment. Injections should not be given in epilepsy and tetany.

DRUG INTERACTIONS:
Butadion, administered together with anticoagulants, oral antidiabetic agents, cytostatics, sulfonamides, nelidix, etc., considerably potentiates its therapeutic effect. It is slowly excreted out of the body and delays the exretion of some other drugs with their simultaneous intake: amidopyrine, morphine, penicillin, PASA.

DOSAGE AND ADMINISTRATION:
At the beginning of the therapeutic course, adults are given 100-200 mg during meals, 3 times daily, thus ensuring a daily dose of 6-12 mg per kg body weight. After a good therapeutic effect, the maintenance dose is reduced to 200-300 mg once daily, with prolongation of the intervals between intakes. The daily dose for elderly patients and long-term treatment is individually determined, but it is necessarily lower. The treatment course lasts from 2 to 5 weeks.
Children are given a dose of 10 mg/kg body weight, later reduced to 5 mg/kg body weight.

MEDICINAL FORM AND PACKAGE:
Packages with 20 dragees of 200 mg.

STORAGE:
At moderate temperature (15-30° C).

EXPIRY:
2 (two) years.